Medical device launches in regulated markets fail more often than they should, but rarely because of product limitations. The problem typically lies in the sequence of decisions. When media strategy is brought in solely as an execution function, after positioning and creative have already been defined, it loses its most critical role: structuring market access.
In healthcare, media is not simply distribution. It is access, compliance, and commercial viability. And that changes the starting point entirely.
Access architecture
In regulated markets, media strategy defines what is possible before a single line of creative writing is written. Communication restrictions, regulatory requirements, and segmentation constraints make it unworkable to conceive “ideal” campaigns without first understanding where and how they can realistically exist.
Recent developments in the regulatory environment, including reinforced post-market surveillance requirements overseen by the Medicines and Healthcare products Regulatory Agency, indicate that scrutiny of medical devices is intensifying, and this extends to how they are communicated. Safety, transparency, and traceability are not merely clinical requirements; they carry direct implications for media and messaging alike.
This means that the selection of channels, formats, and placement environments is not a tactical afterthought. It determines whether the campaign is viable from the outset.
Audience access determines the plan, not the other way around
Unlike conventional consumer categories, audience access in healthcare is highly conditional. For medical devices, this may involve restrictions on direct-to-consumer communication; a requirement for healthcare professional mediation; constraints on language, claims, and context; and dependence on specific editorial environments.
In practice, this inverts the conventional marketing logic. Rather than defining a message and subsequently identifying channels through which to deliver it, the process must begin by mapping the available channels and constructing viable messages from within those parameters. Without this foundational alignment, campaigns frequently encounter rework, scope reductions, or even regulatory non-viability at advanced stages of development.
Early planning prevents invisible cost
When media planning enters the process too late, the consequences extend well beyond performance, they manifest as structural cost. Last-minute revisions to align creative with permitted channels, adjustments to meet regulatory requirements, or the need to rebuild entire customer journeys are common when planning does not begin with media. The result is creative rework, production waste, go-to-market delays, and the loss of critical commercial opportunities.
HCP vs consumer
Another recurring error is treating healthcare professional and consumer strategies as entirely separate workstreams. In medical devices, these two audiences are deeply interdependent. Whilst HCP campaigns require highly specialised environments and rigorous compliance, consumer-facing initiatives must navigate language restrictions, education obligations, and awareness considerations, all without breaching regulatory guidelines.
Recognising and planning for this interdependency from the outset is essential to building a coherent and compliant launch strategy.
The role of publisher ecosystems
Where a brand appears is as consequential as what it says. Curated publisher ecosystems offer something that open platforms can rarely guarantee: context, credibility, and control. Direct partnerships with specialist health publishers enable stronger alignment with regulatory guidelines and editorially trustworthy environments; more precise audience segmentation without reliance on sensitive data; and a higher standard of brand safety.
Beyond inventory, these ecosystems function as launch infrastructure, particularly when access to the target audience is inherently restricted.
Why independent agencies carry greater strategic weight
When media must lead, the choice of strategic partner becomes critical. Independent agencies with deep healthcare expertise tend to operate with greater neutrality in channel selection and a more thoroughgoing command of the regulatory landscape. Unlike structures driven by volume targets or commercial agreements with platforms, these agencies are positioned to prioritise regulatory viability ahead of scale; construct plans based on genuine audience access rather than available inventory; integrate media, data, and compliance considerations from the very beginning; and reduce conflicts of interest in channel selection.
The media-first brief
When media strategy leads, the nature of the brief changes fundamentally. Rather than beginning with messages, it begins with actual constraints and real opportunities, setting out who can be reached and where; which environments are both permissible and effective; which data can be used safely; and how the customer journey is constructed within these parameters.
Only once this foundation is established do positioning, narrative, and creative execution follow. This model does not constrain creativity – it directs it towards territories that are both viable and demonstrably more effective.
